LONDON (Alliance News) - Biopharmaceutical company Motif Bio PLC on Friday said it has signed a clinical trials deal with Covance for its iclaprim antibiotic designed to fight multi-drug-resistant bacteria.
Covance, a clinical research organisation, will run two randomised, double-blind, multi-centre phase 3 trials on iclaprim to evaluate the efficacy and safety of intravenous iclaprim versus intravenous vancomycin in the treatment of acute bacterial skin and skin structure infections.
"The signing of this agreement with Covance is a great step forward for Motif and its development strategy for iclaprim, and ensures a timely start of the Phase III programme," said David Huang, Motif Bio's chief medical officer.
Shares in Motif were up 3.3% to 63.00 pence early Friday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.